UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

Clinical pharmacology and therapeutics, 2008-01, Vol.83 (1), p.106-114

2008

Volltextzugriff (PDF)

Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3687-3693

2008

Volltextzugriff (PDF)

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The Journal of neuroscience, 2011-11, Vol.31 (46), p.16507-16516

2011

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review

Clinical pharmacokinetics, 2001, Vol.40 (3), p.189-205

2001

Volltextzugriff (PDF)

Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer’s Disease

The Journal Of Prevention of Alzheimer's Disease, 2019, Vol.6 (2), p.135-138

2019

Volltextzugriff (PDF)

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384

Translational psychiatry, 2013-08, Vol.3 (8), p.e295-e295

2013

Volltextzugriff (PDF)

Multiple-Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects

Journal of clinical pharmacology, 2006-04, Vol.46 (4), p.424-432

2006

Volltextzugriff (PDF)

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

Acta neurologica Scandinavica, 1998-04, Vol.97 (4), p.244-250

1998

Volltextzugriff (PDF)

Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects

Journal of clinical pharmacology, 2004-03, Vol.44 (3), p.258-264

2004

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease

Journal of clinical pharmacology, 2001-10, Vol.41 (10), p.1082-1090

2001

Volltextzugriff (PDF)

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

Clinical pharmacokinetics, 2002, Vol.41 (3), p.225-234

2002

Volltextzugriff (PDF)

Obesity, Metabolic Abnormality, and Progression of CKD

American journal of kidney diseases, 2018-09, Vol.72 (3), p.400-410

2018

Volltextzugriff (PDF)

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin

Antimicrobial Agents and Chemotherapy, 1997-06, Vol.41 (6), p.1298-1300

1997

Volltextzugriff (PDF)

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Alzheimer's & dementia, 2012-07, Vol.8 (4), p.295-303

2012

Volltextzugriff (PDF)

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

JAD reports, 2022-01, Vol.6 (1), p.1-15

2022

Volltextzugriff (PDF)

First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease

Clinical neuropharmacology, 2003-05, Vol.26 (3), p.164-169

2003

Volltextzugriff (PDF)

Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P66-P66

2005

Volltextzugriff (PDF)

High-Dose Versus Conventional-Dose Continuous Venovenous Hemodiafiltration and Patient and Kidney Survival and Cytokine Removal in Sepsis-Associated Acute Kidney Injury: A Randomized Controlled Trial

American journal of kidney diseases, 2016-10, Vol.68 (4), p.599-608

2016

Volltextzugriff (PDF)

Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol

The Annals of pharmacotherapy, 2003-10, Vol.37 (10), p.1434-1437

2003

Volltextzugriff (PDF)

β-Amyloid therapies in Alzheimer's disease

Expert opinion on investigational drugs, 2001-04, Vol.10 (4), p.593-605

2001

Volltextzugriff (PDF)

Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine

Clinical neuropharmacology, 2002-03, Vol.25 (2), p.122-123

2002

Volltextzugriff (PDF)

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa

The Annals of pharmacotherapy, 2002-02, Vol.36 (2), p.225-230

2002

Volltextzugriff (PDF)

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris

The American journal of cardiology, 1995-06, Vol.75 (16), p.1102-1106

1995

Volltextzugriff (PDF)

Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods

Antimicrobial Agents and Chemotherapy, 1994-09, Vol.38 (9), p.2073-2077

1994

Volltextzugriff (PDF)

1 – 25 von 624

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(488)
Mit Volltextzugriff
(471)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(572)
Koreanisch
(52)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(25)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review

Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer’s Disease

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384

Multiple-Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects

Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

Obesity, Metabolic Abnormality, and Progression of CKD

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease

Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease

High-Dose Versus Conventional-Dose Continuous Venovenous Hemodiafiltration and Patient and Kidney Survival and Cytokine Removal in Sepsis-Associated Acute Kidney Injury: A Randomized Controlled Trial

Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol

β-Amyloid therapies in Alzheimer's disease

Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris

Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods

Suchergebnisse filtern